MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Genetic and functional analysis of CCDC88C mutations in patients with Parkinson’s disease.

    S. Chen, J. Chen, X. Xie, W. Luo (Hangzhou, China)

    Objective: To investigate the association between rare deleterious CCDC88C variants and PD. Background: SCA40 is a rare form of spinocerebellar ataxia caused by heterozygous mutations…
  • 2023 International Congress

    Double trouble: dystonic tremor due to FXTAS in a SCA1 family

    P. Santurelli, G. Bonato, R. Polli, A. Murgia, M. Carecchio (Padova, Italy)

    Objective: To describe a patient belonging to a SCA1 family, who presented with action tremor and dysmetria but with a different genetic etiology. Background: Spino-Cerebellar…
  • 2023 International Congress

    Apathy in Parkinson’s disease: Relation to autonomic symptoms

    A. Ratajska, J. Goetz, L. Zahodne, C. Etheridge, D. Bowers (Gainesville, USA)

    Objective: Our overall goal was to learn whether apathy would be associated with autonomic symptoms in Parkinson’s disease (PD). We examined whether a) PD patients…
  • 2023 International Congress

    Therapy-associated risk decision making in individuals with multiple system atrophy and Parkinson’s disease, THE YAMSA TRIAL

    A. Bernhardt, M. Oeller, I. Friedrich, E. Kocakavuk, E. Nachman, K. Peikert, M. Roderigo, A. Rossmann, T. Schröter, LO. Wilhelm, F. Gandor, J. Levin, A. Giese, A. Janzen, WH. Oertel (Munich, Germany)

    Objective: This study aimed to quantify the risk willingness of patients suffering from the α-synucleinopathies multiple system atrophy (MSA) and Parkinson's Disease (PD) and identify…
  • 2023 International Congress

    Is a Parkinson’s Sialorrhoea service effective?

    C. Williams, J. Adenwalla, B. Mohamed, C. Marquis, C. Thomas, R. Lewis-Morton (cardiff, United Kingdom)

    Objective: Evaluate the efficacy and tolerance of Botulinum Toxin A (BoNT A) in managing sialorrhoea in People with Parkinsons (PwP)Assess impact on quality of life…
  • 2023 International Congress

    Prevalence and clinical characteristics of young onset Parkinson’s Disease among Nepalese Population

    R. Ojha, B. Gajurel, R. Karn, R. Rajbhandari (Kathmandu, Nepal)

    Objective: To know the prevalence and clinical characteristics of young onset Parkinson’s Disease among Nepalese Population Background: Parkinson’s disease (PD) is a neurodegenerative disease which…
  • 2023 International Congress

    “Grab-the-lock test “ – A novel clinical test for identification of dorsolateral Subthalamic nucleus [STN] during deep brain stimulation [DBS]

    A. Panwar, N. Sawal, M. Matta (SAS Nagar, India)

    Objective: The  target during STN DBS  for Parkinson’s disease is the dorsolateral STN which plays a major role in motor functions in contrast to the venteromedial…
  • 2023 International Congress

    Cued movement preparation and movement coding in human thalamic neurons

    M. Baaske, A. Gulberti, A. Engel, M. Heise, W. Hamel, C. Gerloff, M. Pötter-Nerger, A. Sharott, C. Moll (Lübeck, Germany)

    Objective: To study motor cognition in the human motor thalamus at the single cell and population level. Background: The motor thalamus, in particular its cerebellar-receiving…
  • 2023 International Congress

    Safety and pharmacokinetics of anti-inflammatory NE3107 treatment in carbidopa/levodopa-treated patients with Parkinson’s disease: A phase 2a, double-blind, placebo-controlled study

    J. Aldred, R. Rodriguez, E. Rivera-Rivera, S. Isaacson, R. Kumar, A. Ellenbogen, C. Ahlem, C. Reading, J. Palumbo, N. Osman, A. Lang (Spokane, USA)

    Objective: To assess the safety, tolerability, and pharmacokinetics (PK) of NE3107 in carbidopa/levodopa (C/L)-treated patients with Parkinson’s disease (PD) Background: Disease-modifying therapies that augment the…
  • 2023 International Congress

    The effect of levodopa on the blood activity of calpains in patients with Parkinson’s disease

    Z. Muruzheva, M. Absalyamova, M. Karpenko (Saint-Petersburg, Russian Federation)

    Objective: To evaluate the effect of levodopa on the blood activity of calpains in patients with PD Background: Parkinson's disease (PD) is a chronic progressive…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 186
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley